Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Research & Development (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Research & Development data on record, last reported at $9.3 million in Q3 2025.

  • For Q3 2025, Research & Development rose 1.92% year-over-year to $9.3 million; the TTM value through Sep 2025 reached $35.8 million, down 26.55%, while the annual FY2024 figure was $40.0 million, 53.87% down from the prior year.
  • Research & Development reached $9.3 million in Q3 2025 per TNXP's latest filing, down from $10.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $26.5 million in Q1 2023 and bottomed at $7.4 million in Q1 2025.
  • Average Research & Development over 3 years is $14.0 million, with a median of $10.8 million recorded in 2025.
  • Peak YoY movement for Research & Development: plummeted 56.7% in 2024, then grew 11.57% in 2025.
  • A 3-year view of Research & Development shows it stood at $17.1 million in 2023, then plummeted by 51.54% to $8.3 million in 2024, then grew by 11.96% to $9.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $9.3 million in Q3 2025, $10.8 million in Q2 2025, and $7.4 million in Q1 2025.